Vancomycin IV


C. diff Risk


Oral Bioavailability


Approximate Cost


25mg/kg IV loading dose rounded to nearest 250mg.

15mg/kg IV q8-12h maintenance depending on trough goal.


For specific dosing and guidance contact Pharmacy

Therapy is UNRESTRICTED for the first 72 hours of therapy after which Infectious Diseases service approval is required for continuation of therapy (see below for exceptions/rules).

Approval may be granted via phone conversation or formal consult and must be reflected in the patient orders section.

The following conditions are also in place:

  •  Nephrologists are authorized to prescribe without I.D. approval for nephrological diseases

  •  Vancomycin may be used for surgical prophylaxis for up to 24 hours post-op in patients with documented penicillin allergy or patients who are known to be MRSA carriers/colonized. (I.D. approval is required for continuation of therapy beyond 24 hours).

General Information

Common Usage

Suspected or proven MRSA, coagulase-negative Staphylococcal infections, Enterococcal spp. infections.

Drug Monitoring

General monitoring
1. SCr and urea 2-3 times a week
2. Hydration status

To be drawn 30 minutes prior to the next dose -- timing dependent upon the following parameters:

Trough concentration recommended if:
- Aggressive therapy (i.e., trough concentration 15-20 mg/L)
- Concomitant nephrotoxin (e.g., aminoglycosides, NSAIDs, amphotericin)
- Serious infection (see below)
- Prolonged course of therapy anticipated (greater than 8 days of therapy)
- Class III Obesity(BMI greater than or equal to 40 kg/m2)
- Unstable Renal Function (either deteriorating or improving)
- Renal dysfunction
- Altered Volume of Distribution

Therapeutic drug monitoring NOT generally required for anticipated short course of therapy (less than equal to 8 days) AND hemodynamically stable and/or surgical prophylaxis.

Goal Trough 15-20 mg/L if treating:

  • Central nervous system infection

  • Deep-seated or sequestered infection (e.g., abscess)

  • Endocarditis

  • Osteomyelitis

  • MRSA pneumonia, skin and soft tissue infection

  • Bacteremia due to proven or suspected MRSA or MSSA in penicillin-allergic patient

  • Other infections due to S.Aureus with Vancomycin MIC greater than or equal to 1 mg/L

Goal Trough 10-15 mg/L if treating:

  • Skin and Soft tissue infection not due to MRSA

  • Urinary tract infection

  • Bloodstream or line infections due to Coagulase Negative Staphylococci (CoNS)

Adverse Effects

  •  Nephrotoxicity

  •  Cytopenias

  •  Rash including Stevens-Johnson Syndrome

  •  Red man syndrome (histamine release- slow down infusion)

Major Interactions

Aminoglycosides may potentiate nephrotoxicity.

May enhance neuromuscular blockade of NM blocking agents.

Careful with concomitant nephrotoxins.

Additional Information

Target levels vary widely based upon site of infection and organism.

Consult Infectious Diseases or Pharmacy for target recommendations and dosing assistance.


Antimicrobial class: Glycopeptide

Pregnancy category: C

Average serum half life: 8 hours

CSF penetration: Moderate

Biliary penetration: Moderate

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Route of Elimination: Renal